Publications by authors named "Zahra Elyaspour"
Prevalence of Microorganisms in Atherosclerotic Plaques of Coronary Arteries: A Systematic Review and Meta-Analysis.
Evid Based Complement Alternat Med
December 2022
Article Synopsis
- This systematic review and meta-analysis examined the presence of pathogens in atherosclerotic plaques of coronary arteries in patients with coronary artery disease (CAD).
- A comprehensive search was conducted on four major English databases, and the quality of the articles was assessed using a checklist from The Joanna Briggs Institute (JBI).
- The findings revealed that specific microorganisms were prevalent in the plaques, suggesting that these pathogens may play a significant role in the progression of atherosclerosis.
Article Synopsis
- The impact of COVID-19 on vascular health reveals that endothelial cells are crucial targets of the virus, leading to potential complications like coagulopathies and thrombotic issues, which can be life-threatening.
- Evidence suggests that endothelial dysfunction relates to the severity of COVID-19 outcomes, but it's still unclear if this dysfunction is directly caused by the virus or by the body's overwhelming immune response (cytokine storm).
- Therapeutic strategies focusing on stabilizing endothelial function are being explored, highlighting that COVID-19 may also be viewed as a systemic vascular disease needing further investigation to lower mortality rates.
Aims: Incidence of type 2 diabetes is markedly rising worldwide. Some studies suggest that the occurrence of major adverse cardiac events (MACE) after PCI is different in men and women, but data are conflicting.
Methods: We studied patients with stable coronary artery disease (CAD) who underwent PCI between years 2000 and 2017.
The coronavirus disease (COVID-19) pandemic is a global health priority. Given that cardiovascular diseases (CVD) are the leading cause of morbidity around the world and that several trials have reported severe cardiovascular damage in patients infected with SARS-CoV-2, a substantial number of COVID-19 patients with underlying cardiovascular diseases need to continue their medications in order to improve myocardial contractility and to prevent the onset of major adverse cardiovascular events (MACEs), including heart failure. Some of the current life-saving medications may actually simultaneously expose patients to a higher risk of severe COVID-19.
View Article and Find Full Text PDF